GT Biopharma stock heads toward SITC presentation on November 6
Published on 11/05/2026 at 02:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSITC presentation puts pipeline in focus
- GT Biopharma will present research linking KRAS inhibition with NK-cell immunotherapy in pancreatic cancer.
- The company is scheduled to present at the SITC 2026 Annual Meeting in Phoenix, Arizona.
- The event provides a near-term scientific milestone for the clinical-stage immuno-oncology developer.
GT Biopharma announced on October 26, 2026, that it had been selected for an oral presentation at the Society for Immunotherapy of Cancer 2026 Annual Meeting. The company said the presentation will address how inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK-cell immunotherapy. The announcement was published by GlobeNewswire on behalf of GT Biopharma.
What investors should watch next
The presentation is scheduled for Friday, November 6, during the SITC meeting in Phoenix, Arizona. It is assigned to session 106a, Combination Therapies Involving Cell Therapy, and is scheduled from 3:05 to 3:20 p.m. Mountain Time. Paarth Dodhiawala of the University of Minnesota Medical School is listed as the presenter.
The scientific focus places GT Biopharma's TriKE platform in the context of efforts to extend immune-cell therapies into solid tumors. The company release highlights challenges including antigen heterogeneity, immunosuppressive tumor environments and nutrient deprivation. The presentation may therefore give investors a closer look at the research rationale behind the company's development strategy, but it is not a clinical efficacy result or a regulatory approval.
Platform and business focus
GT Biopharma is a clinical-stage biopharmaceutical company focused on immuno-oncology products based on its proprietary TriKE natural killer-cell engager platform. The platform is designed to harness and enhance the cancer-killing abilities of a patient's natural killer cells. The company is headquartered in San Francisco and holds an exclusive worldwide license from the University of Minnesota to develop and commercialize TriKE-based therapies.
GT Biopharma at a glance
- Company: GT Biopharma, Inc.
- Ticker: GTBP
- ISIN: US36254L4077
- Listing: Nasdaq
- Focus: Clinical-stage immuno-oncology and TriKE natural killer-cell engager therapies
- Upcoming event: SITC 2026 oral presentation on November 6, 2026
US equities are tracked through the S&P 500 market environment.
